Kreon 35 000

Pancreatin, the active ingredient in Kreon 35 000, is a pancreatic enzyme presented as 35,000 lipase units per delayed‑release capsule for oral use. It treats exocrine pancreatic insufficiency and related digestive disorders in patients such as those with cystic fibrosis, chronic pancreatitis, or pancreatic cancer.

GNH USA supplies Kreon 35 000 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with distribution networks across Europe, Asia, Africa and the Americas, and the Middle East.

Kreon 35 000 provides pancreatic enzymes that aid digestion in conditions characterized by exocrine pancreatic insufficiency.

- Exocrine pancreatic insufficiency: restores normal digestion of fats, proteins and carbohydrates, reducing steatorrhea and malnutrition. - Cystic fibrosis: improves nutrient absorption and weight gain by supplementing deficient pancreatic enzymes. - Chronic pancreatitis: alleviates malabsorption symptoms and supports caloric intake during disease progression. - Pancreatic cancer: assists with digestive function when tumor or treatment impairs pancreatic enzyme production.

Kreon 35 000 may cause a range of gastrointestinal and allergic reactions, varying from mild to severe.

Common Side Effects: - Abdominal discomfort: mild pain or cramping after meals. - Flatulence: increased intestinal gas production. - Diarrhea: loose stools, sometimes oily. - Nausea: feeling of sickness. - Constipation: reduced bowel movements. - Oily or fatty stools: steatorrhea due to unabsorbed fat.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, or anaphylaxis. - Severe abdominal pain: may indicate intestinal obstruction. - Pancreatitis exacerbation: worsening of pancreatic inflammation. - Fecal impaction: hard stool blockage. - Respiratory distress: rare but possible in severe allergy.

Before prescribing Kreon 35 000, clinicians should consider several precautionary measures to ensure safe use.

- Dose adjustment: required in patients with renal or hepatic impairment. - Monitoring: observe for signs of malabsorption or worsening gastrointestinal symptoms. - Allergy: avoid in individuals with known hypersensitivity to pork-derived proteins. - Pregnancy: safety not established; use only if potential benefit justifies potential risk. - Drug interactions: review concomitant use of antacids, proton pump inhibitors and other enzyme‑affecting agents. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Kreon 35 000 can interact with certain medications that affect gastric pH or enzyme activity.

Major Interactions (Avoid): - Proton pump inhibitors: raise gastric pH and may reduce enzyme activation. - Antacids containing aluminum or magnesium: can bind pancreatic enzymes and diminish efficacy. - Orlistat: may interfere with lipase activity and reduce fat digestion. - H2‑blockers: may also reduce enzyme activation.

Moderate Interactions (Monitor Closely): - Tetracycline antibiotics: may chelate with enzymes, affecting absorption. - Corticosteroids: increase risk of gastrointestinal irritation when combined. - Warfarin: monitor INR as altered vitamin K absorption may affect anticoagulation.